Clinical trials: Diabete Type 2
Diabetes Mellitus, Type 2, Insulin Resistance
The Aging Endocrine Pancreas: Characterization of the Entero-insular Axis Physiology in the Elderly
Like most endocrine axes, the entero-insular axis is expected to go through an age-related physiological deterioration, what might contribute to special features of the elderly onset type 2 diabetes in comparison to middle-age.
- Trial name
- NCT00843479
- Where
- Brazil
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Campinas, Brazil
Diabetes Mellitus, Type 2
Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial
This study was the extension of the LANTU_C_02761 study named EASIE and identified as NCT00751114 (core study comparing insulin glargine versus sitagliptin in insulin-naïve patients treated with metformin and not adequately…
- Trial name
- NCT00851903
- Testing
- Insulin Glargine, Sitagliptin, Metformin
- Where
- 16 sites in United States, Austria and 14 more
- Volunteers
- 112 people
- Sponsor
- Sanofi
Diabetes Type 2, Diabetes Mellitus
Evaluating Use of Continuous Glucose Monitors in a Short-term 2x2-Crossover Study
This 5-week, double-blind, placebo-controlled, 2x2 crossover pilot study investigate the potential of collecting robust, real-time clinical study measures of glucose levels using Abbott Freestyle Libre Continuous Glucose…
- Trial name
- NCT04424888
- Testing
- WB-011, Continuous Glucose Monitor
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pendulum Therapeutics
Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes
The purpose of this study is to compare the effect of the study drug tirzepatide to insulin degludec on blood sugar levels in participants with type 2 diabetes. The study will last about 67 weeks and may include up to 22 visits.
- Trial name
- SURPASS-3 (NCT03882970)
- Testing
- Tirzepatide, Insulin Degludec
- Where
- 122 sites in United States, Argentina and 11 more
- Volunteers
- 1,444 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on Bioavailability
The objective of the current study is to determine the relative bioavailability of a BI 10773 / metformin fixed dose combination tablet compared to single tablets of BI 10773 and metformin when administered together and to assess…
- Trial name
- NCT01211197
- Testing
- C: BI 10773 / metformin tablet, B: BI 10773 tablet and metformin tablet, A: BI 10773 / metformin tablet
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus
This was a 52-week, multicenter, non-randomized, open-label, Phase 3 long-term safety study in participants with type 2 diabetes mellitus who have inadequate glycemic control with monotherapy of oral antihyperglycemic medication…
- Trial name
- NCT01468181
- Testing
- LY2189265, Sulfonylureas (SU), Biguanides (BG)
- Where
- 14 sites in Japan
- Volunteers
- 394 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin
Primary Objective: To demonstrate the superiority of Sotagliflozin versus placebo on hemoglobin A1c (HbA1c) reduction in participants with type 2 diabetes (T2D) who have inadequate glycemic control with metformin.
- Trial name
- NCT02926950
- Testing
- Sotagliflozin (SAR439954), Metformin
- Where
- 93 sites in United States, Canada and 2 more
- Volunteers
- 518 people
- Sponsor
- Lexicon Pharmaceuticals
Type 2 Diabetes
How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics
This study is designed to look at how using glargine insulin with oral diabetes medications and exenatide may improve control of blood sugar levels and weight gain in type 2 diabetics. The main study will last 32 weeks.
- Trial name
- MEXELIN (NCT00667732)
- Testing
- exenatide
- Where
- 3 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Obesity, Type 2 Diabetes
Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions
The purpose of this study is to evaluate the efficacy and safety of VI0521 compared to placebo in treatment of obesity in an adult population with obesity related co-morbid conditions.
- Trial name
- NCT00553787
- Testing
- VI-0521
- Where
- 6 sites in United States
- Volunteers
- 2,487 people
- Sponsor
- VIVUS LLC
Type2 Diabetes
Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics - (Protocol 3)
This study allows Type 2 diabetics to receive feedback from a continuous glucose monitor (CGM) as part of an educational program designed to help them better manage their glucose levels.
- Trial name
- CGM_IRB-3 (NCT03290768)
- Testing
- Continuous Glucose Monitor (CGM), Activity Tracker, Coaching
- Where
- United States
- Volunteers
- 358 people
- Sponsor
- Savvysherpa, Inc.
Type 2 Diabetes Mellitus
A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)
This trial is designed to evaluate, in adult participants with Type 2 diabetes mellitus (T2DM) and inadequate glycemic control on sub-maximal metformin mono-therapy (1000 mg/day), the effect of up-titration of metformin plus the…
- Trial name
- NCT02791490
- Testing
- Sitagliptin, Metformin IR
- Volunteers
- 458 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
IGNITE (Impact of Glucose moNitoring and nutrItion on Time in rangE)
The purpose of this study is to learn whether there is a difference in the amount of time glucose (blood sugar) stays within a target range (glucose 70 - 180 mg/dl) when using either continuous glucose monitoring (CGM) or…
- Trial name
- IGNITE (NCT05516797)
- Testing
- Continuous Glucose Monitoring (CGM)
- Where
- United States
- Volunteers
- 178 people
- Sponsor
- HealthPartners Institute
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Glargine Versus NPH in Patients With Chronic Kidney Disease
Chronic kidney disease (CKD) is one of the most common microvascular complications of diabetes mellitus, and it is the leading cause of end stage renal disease on developed countries.
- Trial name
- NCT02451917
- Testing
- Glargine insulin, NPH insulin
- Where
- Brazil
- Volunteers
- 34 people
- Sponsor
- University of Sao Paulo General Hospital
Diabetes Mellitus, Type 2
The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)
The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in patients with type 2 diabetes mellitus who are receiving treatment with metformin and sulphonylurea…
- Trial name
- NCT01106625
- Testing
- Canagliflozin, Metformin, Sulphonylruea
- Where
- 76 sites in United States, Australia and 10 more
- Volunteers
- 469 people
- Sponsor
- Janssen Research & Development, LLC
Diabetes Mellitus, Type 2, Hypertension
The Medication Metronome Project - Study to Facilitate Follow-up Testing Resulting From Prescribed Medications to Improve Patient Safety and Care
This project tests a model of chronic disease medication management in which the decision to initiate or adjust medical therapy is directly linked to a sequence of subsequent clinical actions (e.g.
- Conditions
- Diabetes Mellitus, Type 2, Hypertension, Hyperlipidemia
- Trial name
- NCT01586897
- Testing
- Medication Metronome, Usual Care
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Massachusetts General Hospital
Diabetes Mellitus, Type 2
A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus
The purpose of this study is to assess the effect of canagliflozin relative to placebo on glycated hemoglobin (HbA1c) after 26 weeks of treatment, and to assess the overall safety and tolerability of canagliflozin.
- Trial name
- NCT03170518
- Testing
- Canagliflozin 100 mg, Canagliflozin 300 mg
- Where
- 106 sites in United States, Brazil and 8 more
- Volunteers
- 171 people
- Sponsor
- Janssen Research & Development, LLC
Chronic Kidney Diseases, Type 2 Diabetes
Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management
The goal of this study is to test whether a dipeptidyl peptidase-4 inhibitor, compared with a sulfonylurea, improves time in normal blood glucose range and reduces blood glucose variability.
- Trial name
- CANDY-CANE (NCT02608177)
- Testing
- Linagliptin, Glipizide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Washington
Hyperuricemia, Albuminuria
Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria
The purpose of this clinical research study is to evaluate signals of potential clinical benefit of the combination of Verinurad and Febuxostat in lowering concentrations of circulating uric acid and thus improving kidney or…
- Conditions
- Hyperuricemia, Albuminuria, Type 2 Diabetes
- Trial name
- NCT03118739
- Testing
- Verinurad 9 mg+Febuxostat 80 mg
- Where
- 18 sites in United States
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)
This study will evaluate whether the addition of Sitagliptin treatment provides a greater decrease in A1C levels compared to placebo in participants with inadequate glycemic control on sulfonylurea and metformin combination…
- Trial name
- NCT01076075
- Testing
- Sitagliptin phosphate, Comparator: pioglitazone, Glimepiride or gliclazide
- Volunteers
- 427 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification
This trial is conducted globally. The aim of the trial is to compare sequential addition of insulin aspart versus further dose increase with insulin degludec/liraglutide in subjects with type 2 diabetes mellitus, previously…
- Trial name
- DUAL™ (NCT02100475)
- Testing
- insulin degludec/liraglutide, insulin aspart
- Where
- 60 sites in United States, Argentina and 8 more
- Volunteers
- 31 people
- Sponsor
- Novo Nordisk A/S